3 results match your criteria: "Carremeau University Hospital[Affiliation]"
An Invisible Threat.
Gastroenterology
February 2025
Department of Hepato-Gastroenterology, Carremeau University Hospital, Nîmes, France. Electronic address:
[Pharmacogenetics of aminoglycoside ototoxicity: State of knowledge and practices - Recommendations of the Francophone Network of Pharmacogenetics (RNPGx)].
Therapie
November 2024
Service de pharmacologie, toxicologie et pharmacovigilance, centre de biologie et de recherche en santé (CBRS), CHU de Limoges, 87042 Limoges, France.
Article Synopsis
- Aminoglycosides can cause nephrotoxicity and ototoxicity, which can be monitored, but genetic predispositions related to the MT-RNR1 gene can heighten the risk of ototoxicity from the first dose.* -
- The Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Francophone Pharmacogenetics Network (RNPGx) provide recommendations on genetic testing for variants of the MT-RNR1 gene that affect ototoxicity, emphasizing the need for thorough screening if aminoglycoside treatment can be delayed.* -
- RNPGx recommends testing for specific MT-RNR1 variants before administering aminoglycosides, but acknowledges the challenge of conducting these tests quickly in urgent situations, and
Plasma Uracil as a DPD Phenotyping Test: Pre-Analytical Handling Matters!
Clin Pharmacol Ther
March 2023
Laboratoire de Pharmacologie Clinique et Toxicologie, CHU Besançon, Besançon, France.